A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease

American Journal of Hematology

Volumn 87, Issue 5, 2012, Pages 536-539

  Kutlar, Abdullah ^a   Ataga, Kenneth I ^b   Mcmahon, Lillian ^c   Howard, Joanna ^d   Galacteros, Frederic ^e   Hagar, Ward ^f   Vichinsky, Elliott ^f   Cheung, Anthony T W ^g   Matsui, Neil ^h   Embury, Stephen H ^h  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e HENRI MONDOR HOSPITAL   (France)

^f CHILDREN S HOSPITAL OAKLAND   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h TRF Pharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PADGEM PROTEIN; PENTOSAN POLYSULFATE; VASCULAR CELL ADHESION MOLECULE 1;

BLOOD FLOW VELOCITY; CELL DAMAGE; DRUG ACTIVITY; DRUG SAFETY; ENDOTHELIUM CELL; HUMAN; IC 50; LASER DOPPLER FLOWMETRY; LETTER; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SICKLE CELL ANEMIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACUTE PAIN; ADMINISTRATION, ORAL; ADULT; ANEMIA, SICKLE CELL; ARTERIAL OCCLUSIVE DISEASES; BLOOD FLOW VELOCITY; DOUBLE-BLIND METHOD; EARLY TERMINATION OF CLINICAL TRIALS; ENDOTHELIAL CELLS; HUMANS; MICROCIRCULATION; P-SELECTIN; PENTOSAN SULFURIC POLYESTER; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84859885815     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23147     Document Type: Letter

References (30)

1. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem 1990; 40: 63-279.
2. Francis RB, Johnson CS. Vascular occlusion in sickle cell disease: Current concepts unanswered questions. Blood 1991; 77: 1405-1414.
3. Embury SH, Hebbel RP, Mohandas N, Steinberg MH. Pathogenesis of Vasoocclusion. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, editors. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press; 1994. p. 311-326.
4. Brozovic M, Davies S, Brownell A. Acute admissions of patients with sickle cell disease who live in Britain. Br Med J 1987; 294: 1206-1208.
5. van Tuijn CF, van Beers EJ, Schnog JJ, Biemond BJ. Pain rate and social circumstances rather than cumulative organ damage determine the quality of life in adults with sickle cell disease. Am J Hematol 2010; 85: 532-535.
6. Rodgers GP, Schechter AN, Noguchi CT, et al. Microcirculatory adaptations in sickle cell anemia: Reactive hyperemia response. Am J Physiol 1990; 258(1 Pt 2): H113-120.
7. Cheung AT, Chen PC, Larkin EC, et al. Microvascular abnormalities in sickle cell disease: A computer-assisted intravital microscopy study. Blood 2002; 99: 3999-4005.
8. Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: A curious paradox. Am J Med 2003; 115: 721-728.
9. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: Inflammation and a chronic vasculopathy. Microcirculation 2004; 11: 129-151.
10. Nur E, Biemond BJ, Otten HM, et al. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. Am J Hematol 2011; 86: 484-489.
11. Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: Pathophysiological implications. Proc Natl Acad Sci U S A 1989; 86: 3356-3360.
12. Robinson SD, Frenette PS, Rayburn H, et al. Multiple, targeted deficiencies in selectins reveal a predominant role for P-selectin in leukocyte recruitment. Proc Natl Acad Sci U S A 1999; 96: 11452-11457.
13. Matsui NM, Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 2002; 100: 3790-3796.
14. Embury SH, Matsui NM, Ramanujam S, et al. The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood 2004; 104: 3378-3385.
15. Solovey A, Lin Y, Browne P, et al. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997; 337: 1584-1589.
16. Wood K, Russell J, Hebbel RP, Granger DN. Differential expression of E- and P-selectin in the microvasculature of sickle cell transgenic mice. Microcirculation 2004; 11: 377-385.
17. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 877-889.
18. Chaplin HJr, Monroe MC, Malecek AC, et al. Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J 1989; 66: 574-584.
19. Khew-Goodall Y, Butcher CM, Litwin MS, et al. Chronic expression of P-selectin on endothelial cells stimulated by the T-cell cytokine, interleukin-3. Blood 1996; 87: 1432-1438.
20. Yao L, Pan J, Setiadi H, et al. Interleukin 4 or oncostatin M induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells. J Exp Med 1996; 184: 81-92.
21. Subramaniam M, Koedam JA, Wagner DD. Divergent fates of P- and E-selectins after their expression on the plasma membrane. Mol Biol Cell 1993; 4: 791-801.
22. Takano M, Meneshian A, Sheikh E, et al. Rapid upregulation of endothelial P-selectin expression via reactive oxygen species generation. Am J Physiol Heart Circ Physiol 2002; 283: H2054-2061.
23. Lawrence MB, Kansas GS, Kunkel EJ, Ley K. Threshold levels of fluid shear promote leukocyte adhesion through selectins (CD62L, P, E). J Cell Biol 1997; 136: 717-727.
24. Jung U, Ley K. Mice lacking two or all three selectins demonstrate overlapping and distinct functions for each selectin. J Immunol 1999; 162: 6755-6762.
25. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest 2000; 106: 411-420.
26. Polanowska-Grabowska R, Wallace K, Field JJ, et al. P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler Thromb Vasc Biol 2010; 30: 2392-2399.
27. Simon M, McClanahan RH, Shah JF, et al. Metabolism of [3H]pentosan polysulfate sodium (PPS) in healthy human volunteers. Xenobiotica 2005; 35: 775-784.
28. Höpfner M, Alban S, Schumacher G, et al. Selectin-blocking semisynthetic sulfated polysaccharides as promising anti-inflammatory agents. J Pharm Pharmacol 2003; 55: 697-706.
29. Maffrand JP, Herbert JM, Bernat A, et al. Experimental and clinical pharmacology of pentosan polysulfate. Semin Thromb Hemost 1991; 17 Suppl 2: 186-198.
30. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008; 148: 94-101.